The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Rituximab for the Treatment of IgG4-Related Disease: Lessons From 10 Consecutive Patients
Abstract
Patients with IgG4-related disease (IgG4-RD) typically have elevated serum concentrations of IgG4 and share histopathologic features that are similar across affected organ(s). IgG4-RD patients frequently require prolonged treatment with glucocorticoids and are often unable to taper these medications. Traditional disease-modifying antirheumatic drugs (DMARDs) are generally ineffective. We assessed the clinical and serologic responses to B lymphocyte depletion therapy in 10 consecutive patients with steroid- and DMARD-refractory IgG4-RD.Ten patients with IgG4-RD were treated with rituximab (RTX) (2 infusions of 1000 mg, 15 days apart). Clinical improvement was assessed by monitoring the patient's ability to taper prednisone to discontinuation and to stop DMARDs; by serial measurements of total IgG and IgG subclasses; and by follow-up radiologic assessments guided by the patient's particular pattern of organ involvement. We also developed and retrospectively applied the IgG4-RD Disease Activity Index and Flare Tool.Organ involvement included the pancreas, biliary tree, aorta, salivary glands (submandibular and parotid), lacrimal glands, lymph nodes, thyroid gland, and retroperitoneum. Nine of 10 patients demonstrated striking clinical improvement within 1 month of starting RTX. One patient with advanced thyroid fibrosis associated with Riedel thyroiditis and a history of disease in multiple other organ systems did not have improvement in the thyroid gland, but the disease did not progress to involve new organs. All 10 patients were able to discontinue prednisone and DMARDs following RTX therapy. Significant decreases in IgG concentrations were observed for the IgG4 subclass only. Four patients were re-treated with RTX after 6 months because of either symptom recurrence and increasing IgG4 concentration at the time of peripheral B cell reconstitution (n = 2) or because of physician discretion (n = 2). Repeated courses of RTX maintained their effectiveness and resulted in further decreases in IgG4 concentrations. In patients who had an increased IgG4 concentration at the time of presentation, the level of serum IgG4 appeared to be a reliable measure of disease activity.IgG4-RD is an idiopathic, multiorgan inflammatory disease in which diverse organ manifestations are linked by characteristic histopathologic and immunohistochemical features. Treatment with RTX led to prompt clinical and serologic improvement in refractory IgG4-RD in all patients with active inflammation. Serial treatments with RTX may lead to progressive declines in serum IgG4 concentrations and better disease control. Serum IgG4 concentrations may remain low, and clinical disease activity may remain quiescent even after B cell reconstitution in a significant proportion of patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
M-Type Phospholipase A 2 Receptor as Target Antigen in Idiopathic Membranous Nephropathy
Beck, L. H., Bonegio, R. G. B., Lambeau, G., Beck, D. M., Powell, D. W., Cummins, T. D., Klein, J. B., & Salant, D. J. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810457 · Cited by 2,347
A new clinicopathological entity of IgG4-related autoimmune disease
Kamisawa, T., Funata, N., Hayashi, Y., Eishi, Y., Koike, M., Tsuruta, K., Okamoto, A., Egawa, N., & Nakajima, H. (2003) · Journal of Gastroenterology · doi:10.1007/s00535-003-1175-y · Cited by 1,457
Diagnosis of Autoimmune Pancreatitis: The Mayo Clinic Experience
Chari, S. T., Smyrk, T. C., Levy, M. J., Topazian, M. D., Takahashi, N., Zhang, L., Clain, J. E., Pearson, R. K., Petersen, B. T., Vege, S. S., et al. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.05.017 · Cited by 972
Standard steroid treatment for autoimmune pancreatitis
Kamisawa, T., Shimosegawa, T., Okazaki, K., Nishino, T., Watanabe, H., Kanno, A., Okumura, F., Nishikawa, T., Kobayashi, K., Ichiya, T., et al. (2009) · Gut · doi:10.1136/gut.2008.172908 · Cited by 724
IgG4-Related Disease: A Cross-sectional Study of 114 Cases
Zen, Y., & Nakanuma, Y. (2010) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181f7266b · Cited by 577
Khosroshahi, A., Bloch, D. B., Deshpande, V., & Stone, J. H. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27435 · Cited by 522
Self-citationAutoimmune pancreatitis: proposal of IgG4-related sclerosing disease
Kamisawa, T., & Okamoto, A. (2006) · Journal of Gastroenterology · doi:10.1007/s00535-006-1862-6 · Cited by 466
IgG4-related Sclerosing Disease: A Critical Appraisal of an Evolving Clinicopathologic Entity
Cheuk, W., & Chan, J. K. C. (2010) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e3181ee63ce · Cited by 452
Otsuki, M., Chung, J. B., Okazaki, K., Kim, M.-H., Kamisawa, T., Kawa, S., Park, S. W., Shimosegawa, T., Lee, K., Ito, T., et al. (2008) · Journal of Gastroenterology · doi:10.1007/s00535-008-2205-6 · Cited by 425
Keystone, E., Fleischmann, R., Emery, P., Furst, D. E., van Vollenhoven, R., Bathon, J., Dougados, M., Baldassare, A., Ferraccioli, G., Chubick, A., et al. (2007) · Arthritis & Rheumatism · doi:10.1002/art.23059 · Cited by 337
A clinical overview of IgG4-related systemic disease
Khosroshahi, A., & Stone, J. H. (2011) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e3283418057 · Cited by 328
Self-citationLongterm Safety of Patients Receiving Rituximab in Rheumatoid Arthritis Clinical Trials
van VOLLENHOVEN, R. F., EMERY, P., BINGHAM, C. O., KEYSTONE, E. C., FLEISCHMANN, R., FURST, D. E., MACEY, K., SWEETSER, M., KELMAN, A., & RAO, R. (2010) · The Journal of Rheumatology · doi:10.3899/jrheum.090856 · Cited by 287
Chronic Sclerosing Sialadenitis (Küttner Tumor) Is an IgG4-associated Disease
Geyer, J. T., Ferry, J. A., Harris, N. L., Stone, J. H., Zukerberg, L. R., Lauwers, G. Y., Pilch, B. Z., & Deshpande, V. (2010) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181c811ad · Cited by 251
Self-citationEbbo, M., Daniel, L., Pavic, M., Sève, P., Hamidou, M., Andres, E., Burtey, S., Chiche, L., Serratrice, J., Longy-Boursier, M., et al. (2012) · Medicine · doi:10.1097/md.0b013e3182433d77 · Cited by 243
Treatment approaches to IgG4-related systemic disease
Khosroshahi, A., & Stone, J. H. (2011) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e328341a240 · Cited by 242
Self-citationAutoimmune pancreatitis and IgG4-related sclerosing disease
Kamisawa, T., Takuma, K., Egawa, N., Tsuruta, K., & Sasaki, T. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.81 · Cited by 204
Rituximab Therapy for Refractory Biliary Strictures in Immunoglobulin G4–Associated Cholangitis
Topazian, M., Witzig, T. E., Smyrk, T. C., Pulido, J. S., Levy, M. J., Kamath, P. S., & Chari, S. T. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2007.12.020 · Cited by 178
Church, N. I., Pereira, S. P., Deheragoda, M. G., Sandanayake, N., Amin, Z., Lees, W. R., Gillams, A., Rodriguez-Justo, M., Novelli, M., Seward, E. W., et al. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01531.x · Cited by 165
Treating patients with autoimmune pancreatitis: Results from a long-term follow-up study
Kamisawa, T., Yoshiike, M., Egawa, N., Nakajima, H., Tsuruta, K., Okamoto, A., Frulloni, L., & Cavallini, G. (2005) · Pancreatology · doi:10.1159/000085277 · Cited by 162
Japanese Clinical Guidelines for Autoimmune Pancreatitis
Okazaki, K., Kawa, S., Kamisawa, T., Ito, T., Inui, K., Irie, H., Irisawa, A., Kubo, K., Notohara, K., Hasebe, O., et al. (2009) · Pancreas · doi:10.1097/mpa.0b013e3181b9ee1c · Cited by 158
Artz, A. S., Somerfield, M. R., Feld, J. J., Giusti, A. F., Kramer, B. S., Sabichi, A. L., Zon, R. T., & Wong, S. L. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.0673 · Cited by 158
Optimising corticosteroid treatment for autoimmune pancreatitis
Ghazale, A. H., & Chari, S. T. (2007) · Gut · doi:10.1136/gut.2007.129833 · Cited by 110
Pathological features of IgG4-related sclerosing disease
Smyrk, T. C. (2010) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e328341347b · Cited by 87
Naitoh, I., Nakazawa, T., Ohara, H., Sano, H., Ando, T., Hayashi, K., Tanaka, H., Okumura, F., Miyabe, K., Yoshida, M., et al. (2009) · Internal Medicine · doi:10.2169/internalmedicine.48.2695 · Cited by 66
BAFF inhibition: A new class of drugs for the treatment of autoimmunity
Liu, Z., & Davidson, A. (2011) · Experimental Cell Research · doi:10.1016/j.yexcr.2011.02.005 · Cited by 65
Cited by
Stone, J. H., Zen, Y., & Deshpande, V. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1104650 · Cited by 2,616
Self-citationKamisawa, T., Zen, Y., Pillai, S., & Stone, J. H. (2015) · The Lancet · doi:10.1016/s0140-6736(14)60720-0 · Cited by 1,212
Self-citationType 2 immunity in tissue repair and fibrosis
Gieseck, R. L., Wilson, M. S., & Wynn, T. A. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.90 · Cited by 1,055
International Consensus Guidance Statement on the Management and Treatment of IgG4‐Related Disease
Khosroshahi, A., Wallace, Z. S., Crowe, J. L., Akamizu, T., Azumi, A., Carruthers, M. N., Chari, S. T., Della‐Torre, E., Frulloni, L., Goto, H., et al. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39132 · Cited by 1,064
Self-citationRituximab for IgG4-related disease: a prospective, open-label trial
Carruthers, M. N., Topazian, M. D., Khosroshahi, A., Witzig, T. E., Wallace, Z. S., Hart, P. A., Deshpande, V., Smyrk, T. C., Chari, S., & Stone, J. H. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-206605 · Cited by 726
Self-citation
Metadata
- Authors
- Khosroshahi, A., Carruthers, M. N., Deshpande, V., Unizony, S., Bloch, D. B., & Stone, J. H.
- Venue
- Medicine
- Published
- 2012-01
- Volume
- 91
- Issue
- 1
- Pages
- 57-66
- ISSN
- 0025-7974 (ISSN-L)
- OpenAlex
- W1971271788
- Cited by
- 489
- References
- 25
- FWCI
- 28.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.